Morgan Stanley analyst Drew Ranieri lowered the firm’s price target on Zimmer Biomet to $120 from $130 and keeps an Equal Weight rating on the shares. Based on the firm’s channel checks and discussions with corporates, it thinks Medical Technology, or MedTech, fundamentals look solid heading into Q2, with utilization and volumes still running comparatively high across end-markets. While fundamentals and the environment are good, “positioning probably matters more” as the firm suspects idiosyncratic stock positioning and expectations to be “the key driver of price performance on the day, particularly where shorter-duration money is at play,” the analyst added in a preview for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $120 from $134 at Citi
- Zimmer Biomet price target lowered to $115 from $130 at Evercore ISI
- Zimmer Biomet Enhances Liquidity with New Credit Facilities
- Birkenstock upgraded, Charter initiated: Wall Street’s top analyst calls
- Zimmer Biomet downgraded to Neutral from Overweight at Piper Sandler